Syndax Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Investors need to see if the company is making progress on its medicines and managing its money.
Shows investors how much money the company made and lost, and what executives plan to do next.
Investors want to know what new medicines are coming and how the company's research is progressing.
The company got cash for operations but investors will be diluted if the notes convert to stock.
Employees and executives can now receive stock awards, which dilutes current shareholders' ownership.
Company secured capital to fund research but will owe money back in five years or convert to stock.
Quarterly updates let investors track if the company's cash, expenses, and progress are on track.
Stocky reads Syndax Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Syndax Pharmaceuticals, Inc.'s most recent tracked filing was a 10-Q on 4 Aug 2026: Quarterly results reported for period ending June 30, 2026.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.